Trial · NCT02532010
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
NCT02532010, Phase 2, Terminated, Weill Medical College of Cornell University; results first posted 2018-06-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML. Trials, record NCT02532010. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02532010
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
- NCT number
- NCT02532010
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Pacritinib, Decitabine, Cytarabine
- First posted
- 2015-08-25
- Last updated
- 2018-06-15
- Results first posted
- 2018-06-15
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Remission Rate | 6 months | Complete remission rate is defined as number of subjects with complete remission according to the IWG criteria, which is defined by presence of \<5 percent of blasts in the bone marrow, absence of blasts with Auer rods, absence of extramedullary disease, absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions. |
| Secondary | Overall Survival | 2 years | Survival following treatment to the date of death |
| Secondary | Overall Remission Rate | 6 months | Overall remission rate is defined as number of subjects with complete remission (CR), Complete Remission with incomplete platelet recovery (CRp), Complete Remission with Incomplete Blood Count Recovery (CRi), Partial Remission (PR) according to the IWG criteria. CRi is defined as All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL)), PR is defined as relevant in the setting of phase I and II clinical trials only; all hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pretreatment bone marrow blast percentage by at least 50 percent. |
| Secondary | Relapse-free Survival | From date of complete remission until either AML relapse or death from any cause, whichever came first, assessed throughout the study period up to 2 years | Time from complete remission documentation to either AML relapse or death from any cause. |
| Secondary | Event-free Survival | Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause, assessed throughout the study period up to 2 years | Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause |
| Secondary | Time to Complete Response | From entry on study until complete remission, assessed throughout the study period up to 2 years | Time from entry on study until documentation of complete remission (CR) |
| Secondary | Remission Duration | time from complete remission to AML relapse, assessed throughout the study period up to 2 years. | Time from CR documentation to AML relapse |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Remission Rate | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Remission Rate | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Relapse-free Survival | From date of complete remission until either AML relapse or death from any cause, whichever came first, assessed throughout the study period up to 2 years | months | MEDIAN | |
| SECONDARY | Event-free Survival | Time from entry on study until time at which there is treatment failure, AML relapse, or death from any cause, assessed throughout the study period up to 2 years | months | MEDIAN | |
| SECONDARY | Time to Complete Response | From entry on study until complete remission, assessed throughout the study period up to 2 years | months | MEDIAN | |
| SECONDARY | Remission Duration | time from complete remission to AML relapse, assessed throughout the study period up to 2 years. | months | MEDIAN |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Remission Rate | Arm A: Pacritinib and Decitiabine | 0 | Participants | ||
| Complete Remission Rate | Arm B: Pacritinib and Cytarabine | 0 | Participants | ||
| Overall Survival | Arm A: Pacritinib and Decitiabine | 3 | Participants | ||
| Overall Survival | Arm B: Pacritinib and Cytarabine | 3 | Participants | ||
| Overall Remission Rate | Arm A: Pacritinib and Decitiabine | 0 | Participants | ||
| Overall Remission Rate | Arm B: Pacritinib and Cytarabine | 0 | Participants | ||
| Relapse-free Survival | Arm A: Pacritinib and Decitiabine | NA | Full Range NA to NA | months | |
| Relapse-free Survival | Arm B: Pacritinib and Cytarabine | NA | Full Range NA to NA | months | |
| Event-free Survival | Arm A: Pacritinib and Decitiabine | 2.5 | Full Range 2 to 4 | months | |
| Event-free Survival | Arm B: Pacritinib and Cytarabine | 3 | Full Range 1 to 5 | months |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Pacritinib and Decitiabine | 9 | |
| Overall Study | STARTED | Arm B: Pacritinib and Cytarabine | 4 | |
| Overall Study | COMPLETED | Arm A: Pacritinib and Decitiabine | 0 | |
| Overall Study | COMPLETED | Arm B: Pacritinib and Cytarabine | 0 | |
| Overall Study | NOT COMPLETED | Arm A: Pacritinib and Decitiabine | 9 | |
| Overall Study | NOT COMPLETED | Arm B: Pacritinib and Cytarabine | 4 |
Source ClinicalTrials.gov
Adverse events392
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea | Nervous system disorders | Arm A: Pacritinib and Decitiabine | 7 | 9 | 7 |
| other | nausea | Nervous system disorders | Arm B: Pacritinib and Cytarabine | 4 | 4 | 6 |
| other | anorexia | General disorders | Arm A: Pacritinib and Decitiabine | 3 | 9 | 3 |
| other | anorexia | General disorders | Arm B: Pacritinib and Cytarabine | 2 | 4 | 4 |
| other | dizziness | Nervous system disorders | Arm A: Pacritinib and Decitiabine | 4 | 9 | 4 |
| other | dizziness | Nervous system disorders | Arm B: Pacritinib and Cytarabine | 3 | 4 | 4 |
| other | vomiting | Gastrointestinal disorders | Arm A: Pacritinib and Decitiabine | 4 | 9 | 4 |
| other | vomiting | Gastrointestinal disorders | Arm B: Pacritinib and Cytarabine | 2 | 4 | 5 |
| other | fatigue | General disorders | Arm A: Pacritinib and Decitiabine | 8 | 9 | 8 |
| other | fatigue | General disorders | Arm B: Pacritinib and Cytarabine | 2 | 4 | 3 |
1 to 10 of 392Source ClinicalTrials.gov
See all 392 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: Pacritinib and Decitiabine | 9 | 9 |
| Total, all-cause mortality | Arm B: Pacritinib and Cytarabine | 4 | 4 |
| Total, other adverse events | Arm A: Pacritinib and Decitiabine | 9 | 9 |
| Total, other adverse events | Arm B: Pacritinib and Cytarabine | 4 | 4 |
| Total, serious adverse events | Arm A: Pacritinib and Decitiabine | 9 | 9 |
| Total, serious adverse events | Arm B: Pacritinib and Cytarabine | 4 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm A: Pacritinib and Decitiabine vs Arm B: Pacritinib and Cytarabine: Complete Remission Rate | Trial comparisons |
| Arm A: Pacritinib and Decitiabine vs Arm B: Pacritinib and Cytarabine: Overall Survival | Trial comparisons |
| Arm A: Pacritinib and Decitiabine vs Arm B: Pacritinib and Cytarabine: Overall Remission Rate | Trial comparisons |
| Arm A: Pacritinib and Decitiabine vs Arm B: Pacritinib and Cytarabine: deaths from any cause | Trial comparisons |
| Arm A: Pacritinib and Decitiabine vs Arm B: Pacritinib and Cytarabine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02532010
GET https://conductscience.org/api/trials/v1/NCT02532010/events?page=2